Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47

Bibliography

• Miller YE, Daniels GL, Jones C, Identification of a cell-surface antigen produced by a gene on human chromosome 3 (cen-q22) and not expressed by Rhnull cells. Am J Hum Genet 1987;41:1061-70
   PubMed Web of Science ®Google Scholar
• Frazier WA, Isenberg JS, Kaur S, CD47. UCSD Nat Mol Pages 2010; doi:10.1038/mp.a002870.01 http://www.signaling-gateway.org/molecule/query?afcsid=A002870
   Google Scholar
• Lindberg FP, Lublin DM, Telen MJ, Rh-related antigen CD47 is the signal-transducer integrin-associated protein. J Biol Chem 1994;269:1567-70
   PubMed Web of Science ®Google Scholar
• Poels LG, Peters D, van Megen Y, Monoclonal antibody against human ovarian tumor-associated antigens. J Natl Cancer Inst 1986;76:781-91
   PubMedGoogle Scholar
• Tsai RK, Rodriguez PL, Discher DE. Self inhibition of phagocytosis: the affinity of 'marker of self' CD47 for SIRPalpha dictates potency of inhibition but only at low expression levels. Blood Cells Mol Dis 2010;45:67-74
   PubMed Web of Science ®Google Scholar
• Oldenborg PA, Zheleznyak A, Fang YF, Role of CD47 as a marker of self on red blood cells. Science 2000;288:2051-4
   PubMed Web of Science ®Google Scholar
• Burger P, Hilarius-Stokman P, de Korte D, CD47 functions as a molecular switch for erythrocyte phagocytosis. Blood 2012;119:5512-21
   PubMed Web of Science ®Google Scholar
• Chao MP, Jaiswal S, Weissman-Tsukamoto R, Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010;2:63ra94
   PubMed Web of Science ®Google Scholar
• Roberts DD, Miller TW, Rogers NM, The matricellular protein thrombospondin-1 globally regulates cardiovascular function and responses to stress. Matrix Biol 2012;31:162-9
   PubMed Web of Science ®Google Scholar
• Kaur S, Kuznetsova SA, Pendrak ML, Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1. J Biol Chem 2011;286:14991-5002
   PubMed Web of Science ®Google Scholar
• Maile LA, Capps BE, Miller EC, Glucose regulation of integrin-associated protein cleavage controls the response of vascular smooth muscle cells to insulin-like growth factor-I. Mol Endocrinol 2008;22:1226-37
   PubMed Web of Science ®Google Scholar
• Allen LB, Capps BE, Miller EC, Glucose-oxidized low-density lipoproteins enhance insulin-like growth factor I-stimulated smooth muscle cell proliferation by inhibiting integrin-associated protein cleavage. Endocrinology 2009;150:1321-9
   PubMedGoogle Scholar
• Reinhold MI, Lindberg FP, Plas D, In vivo expression of alternatively spliced forms of integrin-associated protein (CD47). J Cell Sci 1995;108:3419-25
   PubMed Web of Science ®Google Scholar
• Van Niekerk CC, Ramaekers FC, Hanselaar AG, Changes in expression of differentiation markers between normal ovarian cells and derived tumors. Am J Pathol 1993;142:157-77
   PubMedGoogle Scholar
• Buist MR, Kenemans P, Molthoff CF, Tumor uptake of intravenously administered radiolabeled antibodies in ovarian carcinoma patients in relation to antigen expression and other tumor characteristics. Int J Cancer 1995;64:92-8
   PubMedGoogle Scholar
• Nishiyama Y, Tanaka T, Naitoh H, Overexpression of integrin-associated protein (CD47) in rat kidney treated with a renal carcinogen, ferric nitrilotriacetate. Jpn J Cancer Res 1997;88:120-8
   PubMedGoogle Scholar
• Majeti R, Chao MP, Alizadeh AA, CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009;138:286-99
   PubMed Web of Science ®Google Scholar
• Willingham SB, Volkmer JP, Gentles AJ, The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 2012;17:6662-7
   Google Scholar
• Suzuki S, Yokobori T, Tanaka N, CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. Oncol Rep 2012;28:465-72
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Jamieson CH, Pang WW, CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009;138:271-85
   PubMed Web of Science ®Google Scholar
• Bauer PM, Bauer EM, Rogers NM, Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1. Cardiovasc Res 2012;93:682-93
   PubMed Web of Science ®Google Scholar
• Rogers NM, Thomson AW, senberg JS. Activation of parenchymal CD47 promotes renal ischemia-reperfusion injury. J Am Soc Nephrol 2012; In press
   PubMedGoogle Scholar
• Khandelwal S, van Rooijen N, Saxena RK. Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation. Transfusion 2007;47:1725-32
   PubMed Web of Science ®Google Scholar
• Olsson M, Oldenborg PA. CD47 on experimentally senescent murine RBCs inhibits phagocytosis following Fcgamma receptor-mediated but not scavenger receptor-mediated recognition by macrophages. Blood 2008;112:4259-67
   PubMed Web of Science ®Google Scholar
• Odievre MH, Bony V, Benkerrou M, Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease. Haematologica 2008;93:502-10
   PubMed Web of Science ®Google Scholar
• Chang WT, Chen HI, Chiou RJ, A novel function of transcription factor alpha-Pal/NRF-1: increasing neurite outgrowth. Biochem Biophys Res Commun 2005;334:199-206
   PubMedGoogle Scholar
• Gao AG, Lindberg FP, Dimitry JM, Thrombospondin modulates alphavß3 function through integrin-associated protein. J Cell Biol 1996;135:533-44
   PubMed Web of Science ®Google Scholar
• N'Diaye EN, Brown EJ. The ubiquitin-related protein PLIC-1 regulates heterotrimeric G protein function through association with Gbetagamma. J Cell Biol 2003;163:1157-65
   PubMed Web of Science ®Google Scholar
• Frazier WA, Gao A-G, Dimitry J, The thrombospondin receptor integrin-associated protein (CD47) functionally couples to heterotrimeric Gi. J. Biol. Chem 1999;274:8554-60
   PubMed Web of Science ®Google Scholar
• Sick E, Niederhoffer N, Takeda K, Activation of CD47 receptors causes histamine secretion from mast cells. Cell Mol Life Sci 2009;66:1271-82
   PubMed Web of Science ®Google Scholar
• Manna PP, Frazier WA. The mechanism of CD47-dependent killing of T cells: heterotrimeric Gi-dependent inhibition of protein kinase A. J Immunol 2003;170:3544-53
   PubMed Web of Science ®Google Scholar
• Lamy L, Ticchioni M, Rouquette-Jazdanian AK, CD47 and the 19 kDa interacting protein-3 (BNIP3) in T cell apoptosis. J Biol Chem 2003;278:23915-21
   PubMed Web of Science ®Google Scholar
• Zhang J, Ney PA. Role of BNIP3 and NIX in cell death, autophagy, and mitophagy. Cell Death Differ 2009;16:939-46
   PubMed Web of Science ®Google Scholar
• Bras M, Yuste VJ, Roue G, Drp1 mediates caspase-independent type III cell death in normal and leukemic cells. Mol Cell Biol 2007;27:7073-88
   PubMed Web of Science ®Google Scholar
• Kaur S, Martin-Manso G, Pendrak ML, Thrombospondin-1 inhibits vascular endothelial growth factor receptor-2 signaling by disrupting its association with CD47. J Biol Chem 2010;285:38923-32
   PubMed Web of Science ®Google Scholar
• Bauer EM, Qin Y, Miller TW, Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. Cardiovasc Res 2010;88:471-81
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Shiva S, Gladwin M. Thrombospondin-1-CD47 blockade and exogenous nitrite enhance ischemic tissue survival, blood flow and angiogenesis via coupled NO-cGMP pathway activation. Nitric Oxide 2009;21:52-62
   PubMedGoogle Scholar
• Isenberg JS, Ridnour LA, Dimitry J, CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 2006;281:26069-80
   PubMed Web of Science ®Google Scholar
• Miller TW, Isenberg JS, Roberts DD. Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase. Br J Pharmacol 2010;159:1542-7
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Mazzalupo S, Boitano S, Thrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration. Biochemistry 2011;50:7787-99
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Romeo MJ, Yu C, Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. Blood 2008;111:613-23
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Hyodo F, Pappan LK, Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia. Arterioscler Thromb Vasc Biol 2007;27:2582-8
   PubMed Web of Science ®Google Scholar
• Rogers NM, Roberts DD, Isenberg JS. Age-associated induction of cell membrane CD47 limits basal and temperature-induced changes in cutaneous blood flow. Ann Surg 2012; In press
   PubMedGoogle Scholar
• Yao M, Roberts DD, Isenberg JS. Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP. Pharmacol Res 2011;63:13-22
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Maxhimer JB, Hyodo F, Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury. Am J Pathol 2008;173:1100-12
   PubMed Web of Science ®Google Scholar
• Maxhimer JB, Soto-Pantoja DR, Ridnour LA, Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci Transl Med 2009;1:3ra7
   PubMed Web of Science ®Google Scholar
• Soto-Pantoja DR, Miller TW, Pendrak ML, CD47 deficiency confers cell and tissue radioprotection by activation of autophagy. Autophagy 2012; In press
   PubMedGoogle Scholar
• Kang R, Zeh HJ, Lotze MT, The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ 2011;18:571-80
   PubMed Web of Science ®Google Scholar
• Pan S. Molecular mechanisms responsible for the atheroprotective effects of laminar shear stress. Antioxid Redox Signal 2009;11:1669-82
   PubMed Web of Science ®Google Scholar
• Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol 2002;53:503-14
   PubMed Web of Science ®Google Scholar
• Chung J, Wang XQ, Lindberg FP, Thrombospondin-1 acts via IAP/CD47 to synergize with collagen in alpha2beta1-mediated platelet activation. Blood 1999;94:642-8
   PubMed Web of Science ®Google Scholar
• Albanyan AM, Harrison P, Murphy MF. Markers of platelet activation and apoptosis during storage of apheresis- and buffy coat-derived platelet concentrates for 7 days. Transfusion 2009;49:108-17
   PubMed Web of Science ®Google Scholar
• Guo YL, Liu DQ, Bian Z, Down-regulation of platelet surface CD47 expression in Escherichia coli O157:H7 infection-induced thrombocytopenia. PLoS One 2009;4:e7131
   Google Scholar
• Wang X, Frazier WA. The thrombospondin receptor CD47 (IAP) modulates and associates with alpha2beta1 integrin in vascular smooth muscle cells. Mol Biol Cell 1998;9:865-74
   PubMedGoogle Scholar
• Freyberg MA, Kaiser D, Graf R, Proatherogenic flow conditions initiate endothelial apoptosis via thrombospondin-1 and the integrin-associated protein. Biochem Biophys Res Commun 2001;286:141-9
   PubMed Web of Science ®Google Scholar
• Sajid M, Hu Z, Guo H, Vascular expression of integrin-associated protein and thrombospondin increase after mechanical injury. J Investig Med 2001;49:398-406
   PubMedGoogle Scholar
• Isenberg JS, Annis DS, Pendrak ML, Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem 2009;284:1116-25
   PubMed Web of Science ®Google Scholar
• Kanda S, Shono T, Tomasini-Johansson B, Role of thrombospondin-1-derived peptide, 4N1K, in FGF-2-induced angiogenesis. Exp Cell Res 1999;252:262-72
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Ridnour LA, Perruccio EM, Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci USA 2005;102:13141-6
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Pappan LK, Romeo MJ, Blockade of thrombospondin-1-CD47 interactions prevents necrosis of full thickness skin grafts. Ann Surg 2008;247:180-90
   PubMed Web of Science ®Google Scholar
• Hausman MR, Rinker BD. Intractable wounds and infections: the role of impaired vascularity and advanced surgical methods for treatment. Am J Surg 2004;187:44S-55S
   Web of Science ®Google Scholar
• Xing C, Lee S, Kim WJ, Neurovascular effects of CD47 signaling: promotion of cell death, inflammation, and suppression of angiogenesis in brain endothelial cells in vitro. J Neurosci Res 2009;87:2571-7
   PubMedGoogle Scholar
• Isenberg JS, Maxhimer JB, Powers P, Treatment of ischemia/reperfusion injury by limiting thrombospondin-1/CD47 signaling. Surgery 2008;144:752-61
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Hyodo F, Matsumoto K, Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood 2007;109:1945-52
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Romeo MJ, Abu-Asab M, Increasing survival of ischemic tissue by targeting CD47. Circ Res 2007;100:712-20
   PubMed Web of Science ®Google Scholar
• Maile LA, Allen LB, Hanzaker CF, Glucose regulation of thrombospondin and its role in the modulation of smooth muscle cell proliferation. Exp Diabetes Res 2010;2010
   PubMedGoogle Scholar
• Maxhimer JB, Shih HB, Isenberg JS, Thrombospondin-1-CD47 blockade following ischemia reperfusion injury is tissue protective. Plast Reconstr Surg 2009;124:1880-9
   PubMed Web of Science ®Google Scholar
• Hart EC, Charkoudian N. Sympathetic neural mechanisms in human blood pressure regulation. Curr Hypertens Rep 2011;13:237-43
   PubMed Web of Science ®Google Scholar
• Singh M, Mensah GA, Bakris G. Pathogenesis and clinical physiology of hypertension. Cardiol Clin 2010;28:545-59
   PubMed Web of Science ®Google Scholar
• Forstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J 2012;33:829-37; 837a-837d
   PubMed Web of Science ®Google Scholar
• Curwen JO, Musgrove HL, Kendrew J, Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clin Cancer Res 2008;14:3124-31
   PubMed Web of Science ®Google Scholar
• Isenberg JS, Qin Y, Maxhimer JB, Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stress. Matrix Biol 2009;28:110-19
   PubMed Web of Science ®Google Scholar
• Ochoa CD, Yu L, Al-Ansari E, Thrombospondin-1 null mice are resistant to hypoxia-induced pulmonary hypertension. J Cardiothorac Surg 2010;5:32
   PubMedGoogle Scholar
• Chaulet H, Lin F, Guo J, Sustained augmentation of cardiac alpha1A-adrenergic drive results in pathological remodeling with contractile dysfunction, progressive fibrosis and reactivation of matricellular protein genes. J Mol Cell Cardiol 2006;40:540-52
   PubMedGoogle Scholar
• Lindberg FP, Bullard DC, Caver TE, Decreased resistance to bacterial infection and granulocyte defects in IAP-deficient mice. Science 1996;274:795-8
   PubMed Web of Science ®Google Scholar
• Herold S, von Wulffen W, Steinmueller M, Alveolar epithelial cells direct monocyte transepithelial migration upon influenza virus infection: impact of chemokines and adhesion molecules. J Immunol 2006;177:1817-24
   PubMed Web of Science ®Google Scholar
• Azcutia V, Stefanidakis M, Tsuboi N, Endothelial CD47 Promotes Vascular Endothelial-Cadherin Tyrosine Phosphorylation and Participates in T Cell Recruitment at Sites of Inflammation In Vivo. J Immunol 2012;189(5):2553-62
   PubMedGoogle Scholar
• Chin AC, Fournier B, Peatman EJ, CD47 and TLR-2 cross-talk regulates neutrophil transmigration. J Immunol 2009;183:5957-63
   PubMedGoogle Scholar
• Van VQ, Lesage S, Bouguermouh S, Expression of the self-marker CD47 on dendritic cells governs their trafficking to secondary lymphoid organs. EMBO J 2006;25:5560-8
   PubMedGoogle Scholar
• Li Z, Calzada MJ, Sipes JM, Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior. J Cell Biol 2002;157:509-19
   PubMed Web of Science ®Google Scholar
• Matozaki T, Murata Y, Okazawa H, Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. Trends Cell Biol 2009;19:72-80
   PubMed Web of Science ®Google Scholar
• Blazar BR, Lindberg FP, Ingulli E, CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells. J Exp Med 2001;194:541-9
   PubMed Web of Science ®Google Scholar
• Wang C, Wang H, Ide K, Human CD47 expression permits survival of porcine cells in immunodeficient mice that express. SIRPalpha capable of binding to human CD47. Cell Transplant 2011; [Epub ahead of print]
   Google Scholar
• Ide K, Wang H, Tahara H, Role for CD47-SIRPalpha signaling in xenograft rejection by macrophages. Proc Natl Acad Sci USA 2007;104:5062-6
   PubMed Web of Science ®Google Scholar
• Wang H, Madariaga ML, Wang S, Lack of CD47 on nonhematopoietic cells induces split macrophage tolerance to CD47null cells. Proc Natl Acad Sci USA 2007;104:13744-9
   PubMedGoogle Scholar
• Kim MJ, Lee JC, Lee JJ, Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines. Tumour Biol 2008;29:28-34
   PubMed Web of Science ®Google Scholar
• Zhao XW, Kuijpers TW, van den Berg TK. Is targeting of CD47-SIRPalpha enough for treating hematopoietic malignancy? Blood 2012;119:4333-4; author reply 4334-5
   PubMedGoogle Scholar
• Zhao XW, van Beek EM, Schornagel K, CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci USA 2011;108:18342-7
   PubMed Web of Science ®Google Scholar
• Ticchioni M, Deckert M, Mary F, Integrin-associated protein (CD47) is a comitogenic molecule on CD3-activated human T cells. J Immunol 1997;158:677-84
   PubMed Web of Science ®Google Scholar
• Wilson KE, Li Z, Kara M, beta1 integrin- and proteoglycan-mediated stimulation of T lymphoma cell adhesion and mitogen-activated protein kinase signaling by thrombospondin-1 and thrombospondin-1 peptides. J Immunol 1999;163:3621-8
   PubMed Web of Science ®Google Scholar
• Li Z, He L, Wilson KE, Thrombospondin-1 inhibits TCR-mediated T lymphocyte early activation. J Immunol 2001;166:2427-36
   PubMed Web of Science ®Google Scholar
• Reinhold MI, Lindberg FP, Kersh GJ, Costimulation of T cell activation by integrin-associated protein (CD47) is an adhesion-dependent, CD28-independent signaling pathway. J Exp Med 1997;185:1-11
   PubMedGoogle Scholar
• Reinhold MI, Green JM, Lindberg FP, Cell spreading distinguishes the mechanism of augmentation of T cell activation by integrin-associated protein/CD47 and CD28. Int Immunol 1999;11:707-18
   Google Scholar
• Piccio L, Vermi W, Boles KS, Adhesion of human T cells to antigen-presenting cells through SIRPbeta2-CD47 interaction costimulates T-cell proliferation. Blood 2005;105:2421-7
   PubMed Web of Science ®Google Scholar
• O'Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 2010;327:1098-102
   PubMed Web of Science ®Google Scholar
• Latour S, Tanaka H, Demeure C, Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-alpha: down-regulation of IL-12 responsiveness and inhibition of dendritic cell activation. J Immunol 2001;167:2547-54
   PubMed Web of Science ®Google Scholar
• Avice MN, Rubio M, Sergerie M, CD47 ligation selectively inhibits the development of human naive T cells into Th1 effectors. J Immunol 2000;165:4624-31
   PubMedGoogle Scholar
• Bouguermouh S, Van VQ, Martel J, CD47 expression on T cell is a self-control negative regulator of type 1 immune response. J Immunol 2008;180:8073-82
   PubMedGoogle Scholar
• Lamy L, Foussat A, Brown EJ, Interactions between CD47 and thrombospondin reduce inflammation. J Immunol 2007;178:5930-9
   PubMed Web of Science ®Google Scholar
• Vallbo C, Damber JE. Thrombospondins, metallo proteases and thrombospondin receptors messenger RNA and protein expression in different tumour sublines of the Dunning prostate cancer model. Acta Oncol 2005;44:293-8
   PubMed Web of Science ®Google Scholar
• Rendtlew Danielsen JM, Knudsen LM, Dahl IM, Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma. Br J Haematol 2007;138:756-60
   PubMed Web of Science ®Google Scholar
• Raetz EA, Perkins SL, Bhojwani D, Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer 2006;47:130-40
   PubMed Web of Science ®Google Scholar
• Suhr ML, Dysvik B, Bruland O, Gene expression profile of oral squamous cell carcinomas from Sri Lankan betel quid users. Oncol Rep 2007;18:1061-75
   PubMedGoogle Scholar
• Chan KS, Espinosa I, Chao M, Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 2009;106:14016-21
   PubMed Web of Science ®Google Scholar
• Nagahara M, Mimori K, Kataoka A, Correlated expression of CD47 and SIRPA in bone marrow and in peripheral blood predicts recurrence in breast cancer patients. Clin Cancer Res 2010;16:4625-35
   PubMedGoogle Scholar
• Sarfati M, Fortin G, Raymond M, CD47 in the immune response: role of thrombospondin and SIRP-alpha reverse signaling. Curr Drug Targets 2008;9:842-50
   PubMed Web of Science ®Google Scholar
• Uluckan O, Becker SN, Deng H, CD47 regulates bone mass and tumor metastasis to bone. Cancer Res 2009;69:3196-204
   PubMed Web of Science ®Google Scholar
• Martin-Manso G, Galli S, Ridnour LA, Thrombospondin-1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity by differentiated U937 cells. Cancer Res 2008;68:7090-9
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Chao MP, Majeti R, Macrophages as mediators of tumor immunosurveillance. Trends Immunol 2010;31:212-19
   PubMed Web of Science ®Google Scholar
• Soto-Pantoja DR, Isenberg JS, Roberts DD. Therapeutic Targeting of CD47 to Modulate Tissue Responses to Ischemia and Radiation. J Genet Syndr Gene Ther 2011;2:1000105
   PubMedGoogle Scholar
• Sick E, Jeanne A, Schneider C, CD47 update: a multi-faceted actor in the tumour microenvironment of potential therapeutic interest. Br J Pharmacol 2012. [Epub Ahead of print]
   PubMedGoogle Scholar
• Manna PP, Frazier WA. CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A. Cancer Res 2004;64:1026-36
   PubMed Web of Science ®Google Scholar
• Rath GM, Schneider C, Dedieu S, Thrombospondin-1 C-terminal-derived peptide protects thyroid cells from ceramide-induced apoptosis through the adenylyl cyclase pathway. Int J Biochem Cell Biol 2006;38:2219-28
   PubMed Web of Science ®Google Scholar
• Soto-Pantoja DR, Miller TW, Pendrak ML, CD47 deficiency confers cell and tissue radioprotection by activation of autophagy. Autophagy 2012;8; In press
   PubMedGoogle Scholar
• Isenberg JS, Martin-Manso G, Maxhimer JB, Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer 2009;9:182-94
   Google Scholar
• Kaur S Roberts DD. CD47 applies the brakes to angiogenesis via vascular endothelial growth factor receptor-2. Cell Cycle 2011;10:10-12
   PubMedGoogle Scholar
• Isenberg JS, Hyodo F, Ridnour LA, Thrombospondin-1 and vasoactive agents indirectly alter tumor blood flow. Neoplasia 2008;10:886-96
   PubMedGoogle Scholar
• Kukreja A, Radfar S, Sun BH, Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease. Blood 2009;114:3413-21
   PubMed Web of Science ®Google Scholar
• Sagawa M, Shimizu T, Fukushima N, A new disulfide-linked dimer of a single-chain antibody fragment against human CD47 induces apoptosis in lymphoid malignant cells via the hypoxia inducible factor-1alpha pathway. Cancer Sci 2011;102:1208-15
   PubMedGoogle Scholar
• Isenberg JS, Romeo MJ, Maxhimer JB, Gene silencing of CD47 and antibody ligation of thrombospondin-1 enhance ischemic tissue survival in a porcine model: implications for human disease. Ann Surg 2008;247:860-8
   Google Scholar
• van Ravenswaay Claasen HH, Eggermont AM, Nooyen YA, Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR. Gynecol Oncol 1994;52:199-206
   PubMed Web of Science ®Google Scholar
• Chao MP, Alizadeh AA, Tang C, Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 2011;71:1374-84
   PubMed Web of Science ®Google Scholar
• Haviv F, Bradley MF, Kalvin DM, Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem 2005;48:2838-46
   PubMed Web of Science ®Google Scholar
• Henkin J, Volpert OV. Therapies using anti-angiogenic peptide mimetics of thrombospondin-1. Expert Opin Ther Targets 2011;15:1369-86
   PubMed Web of Science ®Google Scholar
• Fortin G, Raymond M, Van VQ, A role for CD47 in the development of experimental colitis mediated by SIRPalpha+CD103- dendritic cells. J Exp Med 2009;206:1995-2011
   PubMed Web of Science ®Google Scholar
• Finley MJ, Rauova L, Alferiev IS, Diminished adhesion and activation of platelets and neutrophils with CD47 functionalized blood contacting surfaces. Biomaterials 2012;33:5803-11
   PubMedGoogle Scholar
• Raymond M, Van VQ, Rubio M, Targeting SIRP-alpha protects from type 2-driven allergic airway inflammation. Eur J Immunol 2010;40:3510-18
   PubMedGoogle Scholar
• Yu X, Fukunaga A, Nagai H, Engagement of CD47 inhibits the contact hypersensitivity response via the suppression of motility and B7 expression by Langerhans cells. J Invest Dermatol 2006;126:797-807
   PubMedGoogle Scholar
• Fukunaga A, Nagai H, Noguchi T, Src homology 2 domain-containing protein tyrosine phosphatase substrate 1 regulates the migration of Langerhans cells from the epidermis to draining lymph nodes. J Immunol 2004;172:4091-9
   PubMedGoogle Scholar
• Han MH, Lundgren DH, Jaiswal S, Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice. J Exp Med 2012;209:1325-34
   PubMed Web of Science ®Google Scholar
• Kikuchi Y, Uno S, Kinoshita Y, Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma. Leuk Res 2005;29:445-50
   PubMed Web of Science ®Google Scholar
• Chao MP, Alizadeh AA, Tang C, Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010;142:699-713
   PubMed Web of Science ®Google Scholar
• Chao MP, Tang C, Pachynski RK, Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 2011;118:4890-901
   PubMed Web of Science ®Google Scholar
• Kim D, Wang J, Willingham SB, Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 2012
   Google Scholar
• Soto-Pantoja DR, Miller TW, Frazier WA, Inhibitory signaling through signal regulatory protein-alpha is not sufficient to explain the antitumor activities of CD47 antibodies. Proc Natl Acad Sci USA 2012; In press
   PubMedGoogle Scholar
• Zhao XW, Matlung HL, Kuijpers TW, On the mechanism of CD47 targeting in cancer. Proc Natl Acad Sci USA 2012; In press
   Google Scholar
• Olsson M, Bruhns P, Frazier WA, Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood 2005;105:3577-82
   PubMed Web of Science ®Google Scholar
• Chung J, Gao AG, Frazier WA. Thrombspondin acts via integrin-associated protein to activate the platelet integrin alphaIIbbeta3. J Biol Chem 1997;272:14740-6
   PubMed Web of Science ®Google Scholar
• Subramanian S, Parthasarathy R, Sen S, Species- and cell type-specific interactions between CD47 and human SIRPalpha. Blood 2006;107:2548-56
   PubMed Web of Science ®Google Scholar
• Cirak S, Arechavala-Gomeza V, Guglieri M, Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011;378(9791):595-605
   PubMed Web of Science ®Google Scholar